ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Significant Decrease in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 19,900 shares, a decrease of 22.3% from the December 15th total of 25,600 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.9% of the company’s shares are short sold.

ZyVersa Therapeutics Trading Up 12.0 %

NASDAQ ZVSA opened at $1.49 on Wednesday. ZyVersa Therapeutics has a 52 week low of $0.98 and a 52 week high of $25.00. The firm has a 50 day moving average of $1.19 and a two-hundred day moving average of $2.32.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.